Safety and regulation

Peptide safety, UK regulation, and reporting side effects

PeptideClear is editorial. We do not prescribe, dispense, or supply medicines. This page explains how the four product categories on this site sit inside UK law, what the terms "research peptide", "licensed therapeutic", and "unregulated supplement" actually mean, how PeptideClear evaluates safety claims, and what to do if you experience a side effect. For any clinical decision, the right route is a UK-registered prescriber (GP, GMC-registered private clinician, or GPhC-registered pharmacist prescriber).

Three categories of peptide product, three regulatory regimes

The word "peptide" covers a wide range of compounds. UK law treats them differently depending on what the product claims to do, who is supplying it, and what evidence sits behind it. Three categories matter here.

1. Licensed therapeutic (Prescription Only Medicine)

A licensed therapeutic is a peptide-based medicine that holds a Marketing Authorisation (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA). The MA is the legal permission to market the product in the UK for a specified clinical indication. It is granted after the manufacturer submits clinical-trial data showing the medicine is acceptably safe and effective for that use, and after the MHRA accepts the manufacturing standards.

Licensed peptide-based medicines you may encounter include the GLP-1 receptor agonist class. Examples include semaglutide (sold as Wegovy and Ozempic), tirzepatide (Mounjaro), and liraglutide (Saxenda). These are Prescription Only Medicines (POM). They can only be legally supplied in the UK by a GMC-registered prescriber after a clinical consultation, dispensed by a GPhC-registered pharmacy.

The hallmark of this category: an MHRA-approved Summary of Product Characteristics (SmPC) and a Patient Information Leaflet (PIL). Both are published. Both are legally binding documents. The PIL is what arrives in the box.

2. Research peptide (not for human consumption)

A research peptide is a compound that does not hold an MHRA Marketing Authorisation. UK retailers sell research peptides under a "research use only" framing. This means the legal context for supply is laboratory and academic research, not human consumption. Examples include BPC-157, TB-500, MOTS-c, Ipamorelin, Sermorelin, Tesamorelin, and CJC-1295.

Most research peptides have no clinical-trial dossier supporting a UK marketing authorisation for any human indication. The published literature is largely preclinical (cell-line and animal studies) with limited or no peer-reviewed human randomised controlled trial evidence. This is why no UK clinician can lawfully prescribe most research peptides as a licensed therapeutic.

PeptideClear publishes encyclopedia-style editorial on research peptides. We summarise the published preclinical literature, list UK retailers under the research-use-only framing, and apply the CoA Trust Index to retailer transparency. We do not publish dosing protocols, missed-dose runbooks, or any content that assumes human administration.

3. Unregulated supplement (cosmetic peptide skincare, ingestible collagen)

Cosmetic peptides (GHK-Cu, Matrixyl 3000, Argireline) sit under UK cosmetic-product law, regulated by the Office for Product Safety and Standards (OPSS) and the UK Cosmetics Regulation. The relevant safety question is whether the formulation is safe for topical use at the labelled INCI concentrations.

Ingestible collagen supplements sit under UK food law, regulated by the Food Standards Agency (FSA). Collagen is treated as a food supplement, not a medicine. Claims made on packaging are limited by UK retained EU Regulation 1924/2006 on nutrition and health claims. A collagen brand cannot legally claim to "cure" any condition. PeptideClear scores collagen brands on dose, kDa, source transparency, and third-party testing, not on clinical efficacy claims.

The MHRA Marketing Authorisation pathway in one paragraph

A Marketing Authorisation (MA) is the legal licence the MHRA grants to a manufacturer to market a specific medicine in the UK for a specific clinical indication. To get one, the manufacturer submits a dossier covering quality (how it is made), safety (preclinical and clinical toxicology), and efficacy (Phase I, II, and III randomised controlled trials). The MHRA assesses the dossier. If granted, the MA is published on the MHRA Products database and the medicine becomes a licensed therapeutic. Without an MA, a peptide cannot be lawfully marketed for human use in the UK. This is why most research peptides do not have an MA: no manufacturer has submitted the dossier, because the clinical-trial programme to generate one has not been run.

The UK legal framework that surrounds research peptides

Two statutes are relevant when thinking about the supply and possession of compounds that fall outside the Human Medicines Regulations 2012.

Misuse of Drugs Act 1971

The Misuse of Drugs Act controls substances listed in its schedules as Class A, B, or C controlled drugs. Most research peptides discussed on PeptideClear (BPC-157, MOTS-c, Ipamorelin, and similar) are not scheduled controlled drugs under this Act. That means simple possession is not a criminal offence under this Act. It does not mean the compound is safe, licensed, or appropriate for human use.

Psychoactive Substances Act 2016

The Psychoactive Substances Act 2016 makes it an offence to produce, supply, or import a psychoactive substance for human consumption, where that substance is not otherwise controlled, exempted (such as medicines, food, caffeine, nicotine, alcohol), or excluded. Peptides that are not psychoactive (the majority of research peptides covered on this site) fall outside the scope of this Act. Compounds with central-nervous-system activity may be in scope, depending on the specific compound and how it is supplied.

ASA and CAP code on health-claim advertising

The Advertising Standards Authority (ASA) enforces the UK Code of Non-broadcast Advertising and Direct & Promotional Marketing (the CAP code). Section 12 covers medicines, medical devices, health-related products, and beauty products. The rules that matter for any peptide-related content:

• Health claims must be substantiated by published evidence. Anecdotes are not evidence.
• Prescription Only Medicines (including the GLP-1 class for weight management) cannot be advertised to the public in the UK. Editorial commentary that names a POM in a clinical context is permitted; advertising it is not.
• Before-and-after weight-loss imagery is treated as misleading by the ASA in POM advertising contexts. PeptideClear does not publish such imagery.
• Comparison advertising that names a specific POM is restricted. Editorial comparison that frames category and mechanism (rather than head-to-head product advertising) is permitted.
• Claims that a cosmetic or supplement can "cure", "treat", or "prevent" a medical condition are prohibited unless the product holds the relevant medicines authorisation.

What to do if you experience a side effect

Any adverse reaction to a licensed UK medicine, suspected counterfeit medicine, or medical device can be reported to the MHRA Yellow Card scheme. The scheme is the UK's national pharmacovigilance system. Reports feed directly into MHRA safety surveillance.

For research peptides specifically: there is no equivalent UK reporting scheme, because research peptides are not lawfully supplied for human consumption. If a person has self-administered a research peptide and is experiencing symptoms, the same NHS routes apply (NHS 111, GP, A&E in an emergency). Be honest with the treating clinician about what was taken and when. The clinician's duty is care, not enforcement.

How PeptideClear evaluates safety claims editorially

PeptideClear is not a regulator and not a clinical advisory body. We are an editorial publication that grades evidence. When a retailer, brand, or clinic makes a safety claim, we apply five checks before reporting it.

1. Source tier. Claims sourced from MHRA, NICE, NHS England, the BNF, or peer-reviewed primary literature carry more weight than claims from brand-blog content or unverified user forums. See Trust Review for the full source hierarchy.
2. Regulatory consistency. A claim that contradicts MHRA guidance, NICE guidance, or the relevant PIL is flagged. We do not republish such claims as fact.
3. Plausibility against published mechanism. Claims that go beyond what published preclinical or clinical literature supports are downgraded to "marketing claim" framing rather than "supported claim" framing.
4. Conflict of interest. Claims sourced from parties with a direct commercial interest in the conclusion are flagged inline. This includes manufacturer-sponsored studies presented without that framing.
5. Reproducibility. Single studies, particularly small ones with conflicts, are not treated as settled science. Replication across independent groups raises the weight of the claim.

The output is published as editorial commentary, not clinical advice. Where a reader needs a clinical decision, the page directs to a UK-registered prescriber.

What this page is, and what it is not

This page is a plain-English regulatory map and a route to the Yellow Card scheme. It is not a triage tool. It does not tell you whether a specific compound is safe for you. It does not list contraindications, interactions, or dose limits. Those decisions belong with a UK-registered clinician who knows your history.

For the editorial framework that decides which retailers, clinics, and pharmacies appear on PeptideClear, see Trust Review. For the source hierarchy that decides which claims we report, see editorial policy. For how we are funded and disclose commercial relationships, see how we are funded.

Related: editorial policy · Trust Review · methodology · about.